Source: FirstWord Pharma

Active Biotech: FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of mye...

Read full article »
Annual Revenue
$ < 1M
Tomas Leanderson's photo - President & CEO of Active Biotech

President & CEO

Tomas Leanderson

CEO Approval Rating


Read more